Avenue Therapeutics, Inc. (ATXI) stock
ATXIOTCPharmaceutical PreparationsFiscal year ends December 31
$0.43+0.00 (0.00%)
Close on Oct 16, 2026Market cap $1.42MP/E –Yield –
Avenue Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Avenue Therapeutics's total assets was $1.98M at Jun 30, 2026. For fiscal 2025 it was $2.93M, up 9.7% from the year before. The highest annual figure on record is $22.17M in fiscal 2017.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.93M | +9.7% |
| FY2024 | Dec 31, 2024 | $2.67M | +44.4% |
| FY2023 | Dec 31, 2023 | $1.85M | -73.0% |
| FY2022 | Dec 31, 2022 | $6.85M | +72.9% |
| FY2021 | Dec 31, 2021 | $3.96M | +22.0% |
| FY2020 | Dec 31, 2020 | $3.25M | -63.6% |
| FY2019 | Dec 31, 2019 | $8.92M | +97.0% |
| FY2018 | Dec 31, 2018 | $4.53M | -79.6% |
| FY2017 | Dec 31, 2017 | $22.17M | +11153.8% |
| FY2016 | Dec 31, 2016 | $197.00K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.98M | -52.5% |
| Q1 FY2026 | Mar 31, 2026 | $2.47M | -31.3% |
| Q4 FY2025 | Dec 31, 2025 | $2.93M | +9.7% |
| Q3 FY2025 | Sep 30, 2025 | $3.73M | +41.9% |
| Q2 FY2025 | Jun 30, 2025 | $4.16M | -16.6% |
| Q1 FY2025 | Mar 31, 2025 | $3.59M | +8.6% |
| Q4 FY2024 | Dec 31, 2024 | $2.67M | +44.4% |
| Q3 FY2024 | Sep 30, 2024 | $2.63M | +422.9% |
| Q2 FY2024 | Jun 30, 2024 | $4.99M | +199.4% |
| Q1 FY2024 | Mar 31, 2024 | $3.31M | -60.8% |
| Q4 FY2023 | Dec 31, 2023 | $1.85M | -73.0% |
| Q3 FY2023 | Sep 30, 2023 | $502.00K | -12.7% |
| Q2 FY2023 | Jun 30, 2023 | $1.67M | +65.8% |
| Q1 FY2023 | Mar 31, 2023 | $8.45M | +331.9% |
| Q4 FY2022 | Dec 31, 2022 | $6.85M | +72.9% |
| Q3 FY2022 | Sep 30, 2022 | $575.00K | -16.4% |
| Q2 FY2022 | Jun 30, 2022 | $1.01M | -15.6% |
| Q1 FY2022 | Mar 31, 2022 | $1.96M | +0.6% |
| Q4 FY2021 | Dec 31, 2021 | $3.96M | +22.0% |
| Q3 FY2021 | Sep 30, 2021 | $688.00K | -84.2% |
| Q2 FY2021 | Jun 30, 2021 | $1.19M | -77.7% |
| Q1 FY2021 | Mar 31, 2021 | $1.94M | -71.0% |
| Q4 FY2020 | Dec 31, 2020 | $3.25M | -63.6% |
| Q3 FY2020 | Sep 30, 2020 | $4.35M | -68.6% |
| Q2 FY2020 | Jun 30, 2020 | $5.33M | -66.0% |
| Q1 FY2020 | Mar 31, 2020 | $6.70M | -77.5% |
| Q4 FY2019 | Dec 31, 2019 | $8.92M | +97.0% |
| Q3 FY2019 | Sep 30, 2019 | $13.88M | +163.7% |
| Q2 FY2019 | Jun 30, 2019 | $15.68M | +66.1% |
| Q1 FY2019 | Mar 31, 2019 | $29.76M | +94.9% |
| Q4 FY2018 | Dec 31, 2018 | $4.53M | -79.6% |
| Q3 FY2018 | Sep 30, 2018 | $5.26M | -79.9% |
| Q2 FY2018 | Jun 30, 2018 | $9.44M | -72.8% |
| Q1 FY2018 | Mar 31, 2018 | $15.27M | +7652.8% |
| Q4 FY2017 | Dec 31, 2017 | $22.17M | – |
| Q3 FY2017 | Sep 30, 2017 | $26.18M | – |
| Q2 FY2017 | Jun 30, 2017 | $34.71M | – |
| Q4 FY2016 | Dec 31, 2016 | $197.00K | – |
See a number that looks wrong?